Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma (BVR)

This study has been completed.
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Cephalon
Information provided by (Responsible Party):
University of Rochester
ClinicalTrials.gov Identifier:
NCT00547534
First received: October 18, 2007
Last updated: November 10, 2011
Last verified: November 2011

October 18, 2007
November 10, 2011
October 2007
June 2009   (final data collection date for primary outcome measure)
Number of Participants With Progression Free Survival at 2 Years [ Time Frame: Two years ] [ Designated as safety issue: No ]
To determine the progression-free survival following treatment with the BVR combination in patients with relapsed or refractory indolent and mantle cell non-Hodgkin lymphoma.
To determine the progression-free survival following treatment with the BVR combination in patients with relapsed or refractory indolent and mantle cell non-Hodgkin lymphoma. [ Time Frame: Two years ]
Complete list of historical versions of study NCT00547534 on ClinicalTrials.gov Archive Site
  • Toxicity of Drug Combination in the Subjects [ Time Frame: Two years ] [ Designated as safety issue: Yes ]
  • Overall Response Rate (ORR) [ Time Frame: Two years ] [ Designated as safety issue: No ]
    Overall response rate (ORR)to protocol treatment - Partial response, Complete response, etc.
• Determine safety and toxicity of BVR combination in patients with relapsed or refractory indolent and mantle cell NHL • Determine ORR following BVR combination therapy in patients with relapsed or refractory indolent or mantle cell NHL [ Time Frame: Two years ]
Not Provided
Not Provided
 
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma

The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Non-Hodgkin's Lymphoma
  • Drug: bortezomib
    1.3 mg/m^2 on days 1, 4, 8, 11
    Other Name: Velcade
  • Drug: bendamustine
    90 mg/m^2 days 1 and 4
    Other Name: Treanda
  • Drug: rituximab
    375 mg/m^2 day 1
    Other Name: Rituxan
Experimental: Lymphoma Subjects receiving protocol therapy
Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.
Interventions:
  • Drug: bortezomib
  • Drug: bendamustine
  • Drug: rituximab
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011 Mar 10;117(10):2807-12. doi: 10.1182/blood-2010-11-314708. Epub 2011 Jan 14.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31
October 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Voluntary written informed consent before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Female subject is either post-menopausal or surgically sterilized or willing to use acceptable method of birth control for duration of study.
  • Male subject agrees to use acceptable method for contraception for duration of study.
  • Histologically-confirmed indolent or mantle cell lymphoma, utilizing the World Health Organization (WHO) classification. The biopsy must fulfill one of the following criteria:

    • Follicular lymphoma, grades 1-3
    • Marginal zone lymphoma
    • Small lymphocytic lymphoma (circulating lymphocyte count must be < 5,000)
    • Lymphoplasmacytic lymphoma
    • Mantle cell lymphoma [confirmed by cyclin D1+ or FISH for t(11;14)]
  • Age ≥ 18 years
  • Must have received at least one prior chemotherapy regimen for lymphoma. Patients treated only with antibody therapy or only with radiation therapy are not eligible.
  • Zubrod performance status ≤ 3
  • Patients must have measurable disease or an indication to receive additional therapy

Exclusion Criteria:

  • Patient has platelet count of ≤75,000/mm^3 within 14 days before enrollment.
  • Patient has absolute neutrophil count of < 1,000/mm^3 within 14 days before enrollment.
  • Patient has calculated or measured creatinine clearance of <30 mL/minute within 14 days before enrollment.
  • Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment.
  • Myocardial infarction within 6 months prior to enrollment or has New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
  • Patient has hypersensitivity to boron or mannitol
  • Female subject is pregnant or breast-feeding. Confirmation subject is not pregnant must be established by negative serum ß-human chorionic gonadotropin (ß-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
  • Patient has received chemotherapy or antibody therapy within 28 days before enrollment
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Patient has received other investigational drugs with 14 days before enrollment
  • Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
  • Prior exposure to bendamustine
  • Prior exposure to bortezomib if Time to Progression (TTP) after bortezomib containing regimen was < 6 months. If TTP after bortezomib containing regimen was > 6 months, then patient is allowed to enroll on the study.
  • Patient has concomitant active malignancy requiring therapy
  • Patient is known to be HIV positive (test result not required for enrollment).
  • History of solid organ transplantation, or post transplant lymphoproliferative disorder
  • Patient has history of allogeneic stem cell transplantation.
  • Patient has history of autologous stem cell transplantation or radioimmunotherapy within the previous 4 months.
  • Patient has received any other investigational drugs within 14 days prior to enrollment
  • History of, or clinically apparent CNS lymphoma
  • Any clinically significant abnormality in screening blood chemistry, hematology, or urinalysis results that, in the judgment of the investigator, would impede adequate evaluation of adverse events and/or response to treatment, or that requires aggressive intervention
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00547534
ULYM07054
Yes
University of Rochester
University of Rochester
  • Millennium Pharmaceuticals, Inc.
  • Cephalon
Principal Investigator: Jonathan Friedberg, md University of Rochester
University of Rochester
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP